A Phase 3 interventional study of Oxaliplatin and Paclitaxel in Gastric Cancer and Stomach Neoplasms, sponsored by Fudan University. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-23.
Sponsored by Fudan University · Phase 3, Interventional, and Treatment
This study is designed to compare the efficacy of intraperitoneal paclitaxel in combination with SOX, with SOX alone in the first-line treatment of gastric cancer with malignant ascites
Exclusion Criteria:
Drug: Oxaliplatin · Drug: Paclitaxel · Drug: S-1 (Tegafur, Gimeracil and Oteracil Porassium Capsules)
Drug: Oxaliplatin · Drug: S-1 (Tegafur, Gimeracil and Oteracil Porassium Capsules)
130mg/m2, d1, q3w
40mg/m2 ip，d1、8 ,q3w
40mg/m2 Bid po，d1-14,q3w
overall survival
the internal between the date of enrollment and the date of death or last follow-up.
Time frame: 10 months
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fudan University